Canaccord Genuity Maintains Buy on Arcturus Therapeutics, Raises Price Target to $87
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) and raises the price target from $81 to $87.

March 11, 2024 | 11:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on Arcturus Therapeutics and raises the price target from $81 to $87.
The upgrade in price target by a reputable analyst firm like Canaccord Genuity typically signals a strong bullish sentiment towards the stock, suggesting a positive short-term price movement. The increase from $81 to $87 represents a significant upward revision, indicating improved expectations for the company's performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100